NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 5% down today amid a broader market pullback
Neurosense Therapeutics is trading 5% down at $0.41 amid a broader market pullback. - The S&P 500 was down 0.61% and the Nasdaq Composite was down 1.37% on...
🔴 Neurosense Therapeutics is trading 5% down today with no new company-specific catalyst identified
Neurosense Therapeutics is trading 5.10% down now at $0.43 after no new company-specific catalyst was identified on August 17, 2026. - The latest material...
🟢 Neurosense Therapeutics is trading 5.94% up today — catalyst remains unclear
Neurosense Therapeutics is trading 5.94% up at $0.48, with the catalyst unclear on August 17, 2026. - No new company-specific announcement has been...
🟢 Neurosense Therapeutics is trading 11.59% up in pre-market with no new company-specific announcement identified
Neurosense Therapeutics is trading 11.59% up at $0.51 in pre-market, with no new company-specific announcement identified for August 17, 2026, and the catalyst...
🟢 Neurosense Therapeutics is trading 6.44% up in after-hours trading
Neurosense Therapeutics is trading 6.44% up at $0.48 after no new company-specific announcement was identified for August 14, 2026. - An August 13 CEO letter...
NeuroSense's ALS Drug Funding Hits a Wall — Can a Sub-Dollar Stock Survive Nasdaq's Patience Running Out?
Shares of NeuroSense Therapeutics shifted sharply this week as a CEO letter dated August 13, 2026, laid bare the company's struggle to fund its most important...
🟢 Neurosense Therapeutics is trading 8.46% up today in after-hours trading after PARAGON ALS funding delays
Neurosense Therapeutics is trading 8.46% up at $0.48 after its August 13, 2026 CEO letter detailed delays securing funding for the Phase 3 PARAGON ALS study. -...
🔴 Neurosense Therapeutics is trading 5% down today after CEO letter highlighted funding delays
Neurosense Therapeutics is trading 5% down at $0.45 after its August 13, 2026 CEO letter highlighted delays securing funding for the Phase 3 PARAGON ALS...
🟢 Neurosense Therapeutics is trading 5% up in pre-market
Neurosense Therapeutics is trading at $0.49, up +5.08% in pre-market; the catalyst remains unclear and may reflect low-priced biotech trading activity. - No...
🟢 Neurosense Therapeutics is trading 5.4% up today with no confirmed company-specific catalyst
Neurosense Therapeutics is trading 5.4% up at $0.50, possibly reflecting broader risk-on sentiment, though the catalyst remains unconfirmed. - No fresh...
🔴 Neurosense Therapeutics is trading 5.25% down today
Neurosense Therapeutics is trading at $0.45, down 5.25%, with no fresh company-specific announcement found to clearly explain the decline. - Available...
🟢 Neurosense Therapeutics is trading 5.68% up today on PrimeC regulatory alignment
Neurosense Therapeutics is trading at $0.53, up 5.68%, after its August 6 announcement targeting a December 2026 Health Canada filing for PrimeC. - The...
NeuroSense Nears a Canadian Drug Filing for Its ALS Treatment — But Can an $18 Million Company Deliver on the Promise?
Shares of NeuroSense Therapeutics shifted sharply higher this week, touching $0.56 — up 7.5% from the prior close — after the micro-cap biotech announced it...
NeuroSense Nears a Canadian Drug Filing for Its ALS Treatment — But Can an $18 Million Company Deliver on the Promise?
Shares of NeuroSense Therapeutics shifted sharply higher this week, touching $0.56 — up 7.5% from the prior close — after the micro-cap biotech announced it...
NeuroSense Nears a Canadian Drug Filing for Its ALS Treatment — But Can an $18 Million Company Deliver on the Promise?
Shares of NeuroSense Therapeutics shifted sharply higher this week, touching $0.56 — up 7.5% from the prior close — after the micro-cap biotech announced it...
🔴 Neurosense Therapeutics is trading 5.4% down today with no clear company-specific explanation
Neurosense Therapeutics is trading 5.4% down at $0.51, with no clear company-specific explanation for the decline. - On August 6, 2026, the company announced...
🟢 Neurosense Therapeutics is trading 11.6% up today on continued optimism for its ALS drug PrimeC
Neurosense Therapeutics is trading 11.6% up today at $0.58 as momentum continues to build around the company's lead ALS candidate, PrimeC. • The move extends...
🟢 Neurosense Therapeutics is trading 8% up today on ALS drug submission plans and pipeline optimism
Neurosense Therapeutics is trading at approximately $0.56 (up 8%) as the company continues to see positive momentum from its ALS drug candidate, PrimeC. •...
🔴 Neurosense Therapeutics is trading 17% down today in after-hours trading amid thin liquidity
Neurosense Therapeutics is trading at $0.43 (17% down) in after-hours trading as the sharp move appears driven by low-liquidity volatility rather than a fresh...
🟢 Neurosense Therapeutics is trading 11.4% up today amid biotech sector strength and risk-on mood
Neurosense Therapeutics is trading 11.4% up today at $0.52, benefiting from a broader risk-on mood and a strong session for biotech shares. • The stock is...